Case Study: Boehringer Ingelheim accelerates drug development with Lifebit

Boehringer Ingelheim speeds target identification by 90% with Lifebit

Boehringer Ingelheim faced the challenge of securely accessing and analyzing large external biobanks, such as UK Biobank and Genomics England, without moving petabytes of regulated data. Their goals were to standardize this data for joint analysis, ensure governance and privacy, and federate analytics across multiple sources. To address this, they partnered with Lifebit and its federated platform.

Lifebit implemented its platform within Boehringer Ingelheim's own cloud environment, connecting to data sources without copying them. The solution standardized data to a common model and enabled secure, federated analytics. The results included a 90% faster process for target identification, the ability to jointly analyze data from over 500,000 UK Biobank participants, and the execution of over 270 analytical processes. Lifebit's platform provided a secure, governed environment that accelerated drug development.

Boehringer Ingelheim